{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ge LG"],"funding":["Novo Nordisk Foundation"],"pagination":["212"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11767697"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(2)"],"pubmed_abstract":["The overexpression of the epidermal growth factor receptor (EGFR) in certain types of prostate cancers and glioblastoma makes it a promising target for targeted radioligand therapy. In this context, pairing an EGFR-targeting peptide with the emerging theranostic pair comprising the Auger electron emitter cobalt-58m (<sup>58m</sup>Co) and the Positron Emission Tomography-isotope cobalt-55 (<sup>55</sup>Co) would be of great interest for creating novel radiopharmaceuticals for prostate cancer and glioblastoma theranostics. In this study, GE11 (YHWYGYTPQNVI) was investigated for its EGFR-targeting potential when conjugated using click chemistry to N1-((triazol-4-yl)methyl)-N1,N2,N2-tris(pyridin-2-ylmethyl)ethane-1,2-diamine (TZTPEN). This chelator is suitable for binding Co<sup>2+</sup> and C"],"journal":["Molecules (Basel, Switzerland)"],"pubmed_title":["Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics."],"pmcid":["PMC11767697"],"funding_grant_id":["NNF22OC0077099"],"pubmed_authors":["Langkjær N","Danielsen MB","Nielsen AY","Skavenborg ML","McKenzie CJ","Ge LG","Thisgaard H"],"additional_accession":[]},"is_claimable":false,"name":"Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.","description":"The overexpression of the epidermal growth factor receptor (EGFR) in certain types of prostate cancers and glioblastoma makes it a promising target for targeted radioligand therapy. In this context, pairing an EGFR-targeting peptide with the emerging theranostic pair comprising the Auger electron emitter cobalt-58m (<sup>58m</sup>Co) and the Positron Emission Tomography-isotope cobalt-55 (<sup>55</sup>Co) would be of great interest for creating novel radiopharmaceuticals for prostate cancer and glioblastoma theranostics. In this study, GE11 (YHWYGYTPQNVI) was investigated for its EGFR-targeting potential when conjugated using click chemistry to N1-((triazol-4-yl)methyl)-N1,N2,N2-tris(pyridin-2-ylmethyl)ethane-1,2-diamine (TZTPEN). This chelator is suitable for binding Co<sup>2+</sup> and C","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-04T14:05:37.015Z","creation":"2025-04-04T14:05:37.015Z"},"accession":"S-EPMC11767697","cross_references":{"pubmed":["39860082"],"doi":["10.3390/molecules30020212"]}}